Erlotinib Not Recommended For Maintenance Treatment Of Non-Small-Cell Lung Cancer
Links shared publicly online about this topic.
- 184total visits
Erlotinib Not Recommended For Maintenance Treatment Of Non-Small-Cell Lung Cancer
View full resource at medicalnewstoday.com
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Tarceva
Most Recently Shared on June 29, 2011 at 11:05 am By:
Erlotinib Not Recommended For Maintenance Treatment Of Non-Small-Cell Lung Cancer http://mnt.to/3XMf #cancer
Also Shared By:
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer : The Lancet Oncology
thelancet.com — “NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer. By - Fiona Rinaldi, Elisabeth George, Peter Clark” View full resource at thelancet.com
Most Recently Shared on June 30, 2011 at 10:16 am By:
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer http://t.co/MPoJ8Zq #Oncology
NICE Appraisal Of Erlotinib For Maintenance Treatment Of Non-Small-Cell Lung Cancer
medicalnewstoday.com — “NICE is currently appraising the use of erlotinib (Tarceva, Roche Products) as a maintenance treatment for people with non-small-cell lung cancer who have had first line treatment with chemotherap” View full resource at medicalnewstoday.com
Most Recently Shared on March 11, 2011 at 8:05 am By:
NICE Appraisal Of Erlotinib For Maintenance Treatment Of Non-Small-Cell Lung Cancer http://mnt.to/3S7B #cancer
Pemetrexed recommended for non-small cell lung cancer | News | Nursing Times
nursingtimes.net — “The National Institute For Health and Clinical Excellence has today issued final guidance to the NHS recommending pemetrexed (Alimta, Eli Lilly) for the maintenance treatment of non-small cell lung cancer.” View full resource at nursingtimes.net
Most Recently Shared on June 25, 2010 at 11:27 pm By:
News: Pemetrexed recommended for non-small cell lung cancer http://bit.ly/bjN2CP
NICE recommends pemetrexed for non-small cell lung cancer | News | Nursing Times
nursingtimes.net — “The National Institute For Health and Clinical Excellence has today issued final guidance to the NHS recommending pemetrexed (Alimta, Eli Lilly) for the maintenance treatment of non-small cell lung cancer.” View full resource at nursingtimes.net
Most Recently Shared on June 24, 2010 at 11:08 pm By:
News: NICE recommends pemetrexed for non-small cell lung cancer http://bit.ly/dALt2H
NICE recommends pemetrexed for the maintenance treatment of non-small-cell lung cancer
nice.org.uk — “NICE recommends pemetrexed for the maintenance treatment of non-small-cell lung cancer” View full resource at nice.org.uk
Most Recently Shared on June 23, 2010 at 10:52 pm By:
H. Jack West, MD Internist, Health Executive, Oncologist, Physician, and Doctor
UK's NICE program recommends Alimta (pemetrexed) as maintenance therapy for advanced non-small cell #lungcancer: http://bit.ly/b81XOW
Erlotinib as Maintenance Treatment in Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase 3 Study - OncologySTAT
oncologystat.com — “Lancet Oncol. 2010 May 20;[Epub Ahead of Print] - F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, E Esteban, O Molinier, W Brugger, I Melezínek, G Klingelschmitt, B Klughammer, G Giaccone” View full resource at oncologystat.com
Most Recently Shared on June 3, 2010 at 10:26 pm By:
OncologySTAT Health Site and Oncology
Story of the Week With Expert Commentary: Erlotinib as Maintenance Treatment in Advanced NSCLC http://tinyurl.com/2f4n5jk
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study : The Lancet Oncology
thelancet.com — “Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. By - Dr Federico Cappuzzo MD, Tudor Ciuleanu MD, Lilia Stelma...” View full resource at thelancet.com
Most Recently Shared on May 20, 2010 at 8:51 am By:
The SATURN trial looks at effect of erlotinib as maintenance therapy after chemotherapy in patients with lung cancer. http://bit.ly/bZn1Jh
OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC
news-medical.net — “OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.” View full resource at news-medical.net
Most Recently Shared on April 29, 2010 at 12:36 pm By:
Lung Cancer News: OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC: OSI Pharmaceu... http://bit.ly/9iUlSD
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer | Business Wire
businesswire.com — “MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. “We are delighted that lung cancer patients and their physicians will have the option of beginning Ta” View full resource at businesswire.com
Most Recently Shared on April 19, 2010 at 3:36 pm By:
Naoto T. Ueno Oncologist, Physician, Doctor, and Internist
RT @cancer_drugs Business Week: FDA Approves Tarceva as Maintenance Therapy 4 Advanced Non-Small Cell Lung #cancer http://bit.ly/9ghaDc
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - MPR
empr.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at empr.com
Most Recently Shared on April 19, 2010 at 3:17 pm By:
MPR News: Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC): Genentech annou... http://bit.ly/aL6GEI
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - ONA
oncologynurseadvisor.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 19, 2010 at 2:54 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) http://goo.gl/fb/8XCZx
Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at news-medical.net
Most Recently Shared on April 17, 2010 at 6:50 am By:
Stroke News: Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC: Genentech, Inc... http://twurl.nl/kuh4rr
FDA Advisory Committee votes against the approval of Tarceva
news-medical.net — “OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemother” View full resource at news-medical.net
Most Recently Shared on December 17, 2009 at 5:01 pm By:
Lung Cancer News: FDA Advisory Committee votes against the approval of Tarceva: OSI Pharmaceuticals, Inc. and Genen... http://bit.ly/7LSOAw
FDA accepts supplemental NDA for Tarceva (erlotinib) for maintenance treatment of NSCLC - MPR
empr.com — “OSI Pharmaceuticals announced that the FDA has accepted for filing and review the supplemental New Drug Application (sNDA) for the use of Tarceva (erlotinib) as a first-line maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy.” View full resource at empr.com
Most Recently Shared on June 16, 2009 at 10:34 pm By:
MPR News: FDA accepts supplemental NDA for Tarceva (erlotinib) for maintenance treatment of NSCLC: OSI .. http://tinyurl.com/nhxeqq
Advertisement
MNT Lung Cancer
@mnt_lungcancer
NICE Appraisal Of Erlotinib For Maintenance Treatment Of Non-Small-Cell Lung Cancer http://mnt.to/3S7B #lungcancer
1 year ago...